Literature DB >> 34038245

Maresin-1 induces cardiomyocyte hypertrophy through IGF-1 paracrine pathway.

Tri Wahyuni1,2, Arisa Kobayashi1, Shota Tanaka1, Yoshiaki Miyake1, Ayaha Yamamoto1, Anton Bahtiar2, Shota Mori1, Yusuke Kametani1, Masashi Tomimatsu1, Kotaro Matsumoto1, Makiko Maeda3, Masanori Obana1,4,5,6, Yasushi Fujio1,5.   

Abstract

The resolution of inflammation is closely linked with tissue repair. Recent studies have revealed that macrophages suppress inflammatory reactions by producing lipid mediators, called specialized proresolving mediators (SPMs); however, the biological significance of SPMs in tissue repair remains to be fully elucidated in the heart. In this study, we focused on maresin-1 (MaR1) and examined the reparative effects of MaR1 in cardiomyocytes. The treatment with MaR1 increased cell size in cultured neonatal rat cardiomyocytes. Since the expression of fetal cardiac genes was unchanged by MaR1, physiological hypertrophy was induced by MaR1. SR3335, an inhibitor of retinoic acid-related orphan receptor α (RORα), mitigated MaR1-induced cardiomyocyte hypertrophy, consistent with the recent report that RORα is one of MaR1 receptors. Importantly, in response to MaR1, cardiomyocytes produced IGF-1 via RORα. Moreover, MaR1 activated phosphoinositide 3-kinase (PI3K)/Akt signaling pathway and wortmannin, a PI3K inhibitor, or triciribine, an Akt inhibitor, abrogated MaR1-induced cardiomyocyte hypertrophy. Finally, the blockade of IGF-1 receptor by NVP-AEW541 inhibited MaR-1-induced cardiomyocyte hypertrophy as well as the activation of PI3K/Akt pathway. These data indicate that MaR1 induces cardiomyocyte hypertrophy through RORα/IGF-1/PI3K/Akt pathway. Considering that MaR1 is a potent resolving factor, MaR1 could be a key mediator that orchestrates the resolution of inflammation with myocardial repair.

Entities:  

Keywords:  IGF-1; cardiomyocyte; hypertrophy; maresin-1; physiology

Year:  2021        PMID: 34038245     DOI: 10.1152/ajpcell.00568.2020

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  4 in total

Review 1.  Protective Potential of Maresins in Cardiovascular Diseases.

Authors:  Min Liu; Huixiang He; Lihong Chen
Journal:  Front Cardiovasc Med       Date:  2022-07-04

2.  CXCL10 is a novel anti-angiogenic factor downstream of p53 in cardiomyocytes.

Authors:  Tri Wahyuni; Shota Tanaka; Ryuta Igarashi; Yoshiaki Miyake; Ayaha Yamamoto; Shota Mori; Yusuke Kametani; Masashi Tomimatsu; Shota Suzuki; Kosei Yokota; Yoshiaki Okada; Makiko Maeda; Masanori Obana; Yasushi Fujio
Journal:  Physiol Rep       Date:  2022-05

3.  Yes-associated protein activation potentiates glycogen synthase kinase-3 inhibitor-induced proliferation of neonatal cardiomyocytes and iPS cell-derived cardiomyocytes.

Authors:  Yusuke Kametani; Shota Tanaka; Yuriko Wada; Shota Suzuki; Ayaka Umeda; Kosuke Nishinaka; Yoshiaki Okada; Makiko Maeda; Shigeru Miyagawa; Yoshiki Sawa; Masanori Obana; Yasushi Fujio
Journal:  J Cell Physiol       Date:  2022-03-21       Impact factor: 6.513

4.  Maresin-1 Prevents Liver Fibrosis by Targeting Nrf2 and NF-κB, Reducing Oxidative Stress and Inflammation.

Authors:  María José Rodríguez; Matías Sabaj; Gerardo Tolosa; Francisca Herrera Vielma; María José Zúñiga; Daniel R González; Jessica Zúñiga-Hernández
Journal:  Cells       Date:  2021-12-03       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.